The Use of Dual Energy X-ray Absorptiometry to Study the Effects of Low-Dose Methotrexate on Bone Density
A study at Deaconess Research Institute was initiated to determine the contribution of low-dose Methotrexate to the development of osteopenia. Findings are based upon analysis of Dual Energy X-ray Absorptiometry (DEXA) scans for bone density and bone mass. Scans were performed 18 to 24 mo apart for 5 of 11 patients currently undergoing low-dose Methotrexate therapy for the treatment of rheumatoid arthritis. The results suggest there is no correlation between low-dosage Methotrexate and osteopenia/osteoporosis and that therapeutic doses seem to pose little threat of significant bone loss.